Abstract
Introduction

58
Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic regions (7, 8) .
80
The prognosis of PEL patients is usually poor with a median survival time of 81 6.2 months (9). There is currently no efficient and specific treatment for PEL (2, 3). 
Results
104
Identification of inhibitors of KSHV-transformed cells. Fig.1A and B) . Interestingly, most of the 119 selected compounds (54%) are anti-inflammatory, followed by antibacterial (10%), 120 antihypertensive (10%), antioxidant (4%), antiviral (2%), antiarthritic (2%), 121 antiangiogenesis (2%) and cathecholaminegic (2%) (Fig. 1C) . Among them, 122 cytarabine, a cytidine analogue with a modified sugar moiety, i.e. arabinose instead 123 of ribose, is currently used for treating leukemia and lymphomas (11) , and hence is 124 an interesting candidate that could be repurposed for KSHV-induced malignancies.
125
To confirm the inhibition efficacy of cytarabine on KSHV-transformed cells, we 126 treated MM and KMM cells with 0, 2.5, 5 and 10 µM of cytarabine over a period of 127 120 h. Cytarabine preferentially inhibited the proliferation of KMM cells in a dose-128 dependent manner ( Fig. 1D and E) . Consistently, cytarabine induced cell cycle arrest 129 in KMM but not MM cells ( Fig. 1F and G) . Furthermore, extended treatment with 130 cytarabine for up to 15 days completely eliminated live KMM cells by day 9 at 10 µM 131 and by day 12 at both 2.5 and 5 µM (Fig. 1I) . In contrast, while cytarabine at 5 and 10 132 7 µM had slight inhibitory effect on MM cells, most cells survived up to day 12; 133 however, most of the cells detached by day 15 albeit they remained alive (Fig. 1H) . PEL lines tested, which manifested a greater sensitivity than BJAB cells ( Fig. 2A-F ).
142
As a result, PEL lines had IC50 ranging from 0.44 µM to 1.29 µM while BJAB cells indicating the lack of any emerging resistance ( Fig. 2H and I ). (Fig. 3C) . In contrast, cytarabine did not induce any apoptosis in BJAB 156 cells ( Fig. 3B and C) . ORF-K8 and ORF65 (Fig. 6B) , and virion production (Fig. 6C) . While sodium butyrate 223 (NaB) robustly induced KSHV lytic replication with increase of lytic transcripts RTA,
224
ORF59 and ORF65 (Fig. 6A) , lytic proteins ORF-K8 and ORF65 (Fig. 6B) , and virion 225 production (Fig. 6C) , cytarabine completely inhibited this effect. These results
226
indicated that cytarabine did not induce, rather it inhibited KSHV lytic replication. 
271
We have demonstrated that cytarabine induces cell cycle arrest and apoptosis 
293
The chemically close fluoro-iodo-cytosine analogue FIAC is efficient against HSV-1, NaB. In addition to KSHV, over 70% of PEL cases are co-infected by EBV, which 307 itself is associated with several cancers (36). Similar to KSHV, EBV lytic replication 308 participates in the spreading and pathogenesis of EBV-associated malignancies (37).
294
HSV-2 and EBV (28, 29). Because of its anti-tumor and anti-viral effects, it would be
309
Since cytarabine does not reactivate EBV from latency, it can be used for PEL 
422
The protocols for the animal experiments were approved by the University of Cytarabine was replenished every 3 days. 
